Clinical Trial Update: Phase II Study of Neoadjuvant XELOX + Lapatinib in HER2(+) Gastric Cancer Patients With Liver Metastasis [Phase 2]

View source ↗

Summary

Phase II study evaluating neoadjuvant XELOX plus lapatinib in HER2-positive gastric cancer with liver metastasis has been completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Gastric Cancer
• Liver Metastasis

Drugs mentioned

• Lapatinib (Lapatinib)
• XELOX (capecitabine + oxaliplatin)

Snippet

Sponsor: Samsung Medical Center | Conditions: HER2-positive Gastric Cancer Patients With Liver Metastasis | Phase 2 | Status: COMPLETED